about
Pharmacological Targeting of the Hepcidin/Ferroportin AxisGenetic disruption of NRF2 promotes the development of necroinflammation and liver fibrosis in a mouse model of HFE-hereditary hemochromatosisERAD defects and the HFE-H63D variant are associated with increased risk of liver damages in Alpha 1-Antitrypsin DeficiencyPathophysiological consequences and benefits of HFE mutations: 20 years of research.Iron and inflammation - the gut reaction.How we manage patients with hereditary haemochromatosis.Iron overload and altered iron metabolism in ovarian cancer.Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.The transferrin receptor: the cellular iron gate.Characterization of ferroptosis in murine models of hemochromatosis.Type 4B hereditary hemochromatosis associated with a novel mutation in the SLC40A1 gene: A case report and a review of the literature.The hepatocyte-specific HNF4α/miR-122 pathway contributes to iron overload-mediated hepatic inflammation.Red blood cell transfusion support and management of secondary iron overload in patients with haematological malignancies in the Netherlands: a survey.Periodontal status and serum biomarker levels in HFE haemochromatosis patients. A case-series study.Hepcidin: a real-time biomarker of iron need.Using iron studies to predict HFE mutations in New Zealand: implications for laboratory testing.Causes of iron overload in blood donors - a clinical study.Identification of new BMP6 pro-peptide mutations in patients with iron overload.TIMP3 deficiency exacerbates iron-overload mediated cardiomyopathy and liver disease.Hepcidin agonists as therapeutic tools.Increased transferrin saturation is associated with subgingival microbiota dysbiosis and severe periodontitis in genetic haemochromatosisIron metabolism disorders in patients with hepatitis B-related liver diseases
P2860
Q26738350-6ED9FF71-F650-4C90-B968-51A9871720F1Q28396243-872B8CB8-DD11-4A68-9E73-44C7697E407EQ33803215-2C4EF55D-4D4D-412C-BD1B-188F2C147FF3Q33815961-5258BFED-6BDD-4706-8AF8-EBFAB9DA9B4DQ34548797-7E86CE76-4DE0-41A6-8842-1D4EFFB68EECQ38813097-CF773A28-5A6C-41B8-850C-E0FB46A79027Q39092091-5E8C446D-BF8D-48F0-B350-2DE056CF13F5Q39179797-13B38E04-49D1-4719-B800-2BB37059D356Q39410864-7D504EF1-B398-4D18-A268-0B7436895180Q40333897-E7523BA9-CB0E-465B-A559-D3B7540788A8Q42123916-01AC8D95-979E-48A1-9A57-2E2FE027FF5AQ46343638-25049035-29AC-4E63-9D68-1E455FB9DB05Q47187831-AB4F7A82-1DB1-455A-9F2F-9145D075722FQ47354020-081417EE-AB60-4236-A4AA-55A191B3212BQ47732977-5CFF1FAC-C8BC-49C1-A537-3BA316C3440FQ48030548-ED6551CE-5A99-4755-900D-4170C76A5771Q48136475-3FE1299C-63B0-48AF-9CC5-32F732A15F12Q48368671-D78F4BEF-9225-4CEB-B3DC-0F91DF6FC17BQ49663340-BB1C9CCE-B05B-47CB-B61E-9F4DA46B2C76Q52663760-75B46F06-111A-4A63-A1C9-44D0EFF42F25Q57811519-7A89B09B-6FAC-48D2-BE5E-85BEB87BB1C7Q59133437-3F0419C8-33D9-46B7-805B-A32179B98DAA
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Haemochromatosis.
@ast
Haemochromatosis.
@en
type
label
Haemochromatosis.
@ast
Haemochromatosis.
@en
prefLabel
Haemochromatosis.
@ast
Haemochromatosis.
@en
P2093
P1433
P1476
Haemochromatosis.
@en
P2093
Lawrie W Powell
Rebecca C Seckington
Yves Deugnier
P304
P356
10.1016/S0140-6736(15)01315-X
P407
P577
2016-03-11T00:00:00Z